It’s possible to defy gravity using sound waves, magnets or electricity, but today’s methods can’t hoist heavy items high in ...

Don’t miss tonight’s exciting Coast 2 Coast Tuesday NBA doubleheader on Peacock. The action starts at 8:00 PM ET when the Philadelphia 76ers host the Orlando Magic. Then, at 11:00 PM, the LA Clippers ...

Lorwyn block. It was originally conceived of as a “world that went through a radical change” as it shifted between light and ...

The US FDA has approved a durvalumab (Imfinzi, AstraZeneca)-based regimen for adults with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). Specifically, durvalumab, an ...

The FDA approved Imfinzi with FLOT chemotherapy for resectable gastric or gastroesophageal junction adenocarcinoma, based on the MATTERHORN trial results. The MATTERHORN trial demonstrated improved ...

It can be hard to wrap your head around exactly what the U.S. Space Force does. Sitting in front of a screen tracking satellites doesn't have the same visceral impact as, say, flying a fighter jet. So ...

Orlando Magic guards Anthony Black and Jalen Suggs had plenty to celebrate during Tuesday's second quarter, when their team scored 51 points, a franchise record for points in any quarter. Bill ...

This approval makes durvalumab with FLOT chemotherapy the first perioperative immunotherapy for resectable gastric or gastroesophageal junction adenocarcinoma. For patients weighing 30 kg or more, the ...

AstraZeneca’s Imfinzi is adding yet another landmark perioperative label to its belt with a new FDA approval that gives the drug the title of the first and only immunotherapy marketed to treat ...

The U.S. Food and Drug Administration has approved Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) for treating adult ...

Based on MATTERHORN Phase III trial results which showed a 29% reduction in the risk of progression, recurrence or death and a 22% reduction in the risk of death for the IMFINZI regimen vs.

Stoboclo and Osenvelt were approved as interchangeable biosimilars for bone loss conditions, potentially reducing costs and increasing access. Darzalex Faspro was approved for high-risk smoldering ...